Description: Nafithromycin | C42H62N6O11S | CID 117587595 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ...
DA: 88 PA: 46 MOZ Rank: 69
Description: Nafithromycin (WCK 4873), a novel lactone-ketolide, was administered to healthy adult subjects in 2 randomized, double-blind, placebo-controlled, Phase 1 studies. In the first-in-human study, single-ascending oral doses of nafithromycin (100 to 1200 mg) were administered to subjects under fasted or …
DA: 37 PA: 58 MOZ Rank: 49
Description: Nafithromycin, a novel lactone ketolide was therefore assessed for hepatic safety through range of preclinical in vitro (metabolic stability, CYP inhibition/induction assays) and in vivo (mass balance and repeat dose toxicity) studies. Repeat-dose toxicity studies in rat and dog revealed that nafithromycin did not cause adverse hematological ...
DA: 12 PA: 40 MOZ Rank: 30
Description: Sep 16, 2016 · Primary Purpose: Treatment. Official Title: A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults.
DA: 71 PA: 73 MOZ Rank: 56
Description: Nafithromycin - Wockhardt Alternative Names: WCK 4873 Latest Information Update: 28 Oct 2019. Price : $50 * Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information ...
DA: 52 PA: 48 MOZ Rank: 13
Description: Structure, properties, spectra, suppliers and links for: nafithromycin, 1691240-78-4.
DA: 65 PA: 25 MOZ Rank: 53
Description: Jul 26, 2017 · INTRODUCTION. Nafithromycin, also known as WCK 4873, is a new orally bioavailable lactone-ketolide currently under development by Wockhardt Bio AG (Switzerland) for the treatment of community-acquired bacterial pneumonia (Fig. 1).Nafithromycin has completed phase 1 single- and multiple-ascending-dose studies in Europe and an intrapulmonary pharmacokinetic study in the …
DA: 32 PA: 87 MOZ Rank: 34
Description: Aug 26, 2021 · Nafithromycin has been designed to overcome resistance in several respiratory pathogens. It would provide a compliance-friendly once-a-day, three-day …
DA: 77 PA: 93 MOZ Rank: 22
Description: Among phase 3 stage pipeline drugs, WCK 4873 (Nafithromycin), a next-generation lactone-ketolide, is currently undergoing phase 3 study for the treatment of community-acquired bacterial pneumonia (CABP). It is comprehensively active against macrolide or penicillin or quinolone-resistant Streptococcus pneumoniae as well as entire range of ...
DA: 10 PA: 61 MOZ Rank: 59